Patel Mona Chetan

Director Patel Mona Chetan bought 312.5K shares of COCH at $0.40 (Feb 2026); part of 5-insider cluster buy amid -28.8% annual revenue decline and negative net income.

Director Patel Mona Chetan purchased 312,500 shares at $0.40 per share on 2026-02-12, increasing her holdings from 20,000 to 332,500 shares—a 1562.5% increase in position size. This transaction is part of a cluster in which 5 other insiders also bought within the past 14 days, suggesting coordinated board-level activity. However, the company's fundamentals present significant headwinds: revenue declined 28.8% year-over-year to $42,000 in the latest quarter, the company generated negative net income of $-6,482,000 over its most recent full fiscal year, and market cap stands at only $19,862,692.59. The insider's same-ticker history at COCH shows 5 prior buys with a 0% win rate at the 90-day mark (all five resulted in losses within 90 days), establishing a pattern of poorly-timed accumulation at this ticker. Current price of $0.69 represents a 59.9% decline from the 52-week high of $1.72, yet the stock remains above the $0.39 52-week low—leaving material downside risk in a cash-constrained, revenue-declining business.

Director Patel Mona Chetan bought 2,500 shares at $1.47 on 2025-06-11; stock now down -19.4% in 30d, -63.2% from 52w high, within weak track record pattern.

Director Patel Mona Chetan purchased 2,500 shares at $1.47 on 2025-06-11, increasing holdings from 17,500 shares to 20,000 shares. This marks the insider's fifth buy at Envoy Medical within nine months, following purchases on 2025-06-06, 2024-11-20, 2024-09-11, and 2024-09-09. Across his prior four buys at this ticker, none resulted in positive 90-day returns—outcomes ranged from -10.9% to -36.8%—revealing a consistent pattern of poorly-timed entry points. The stock is currently trading at $1.37, down 19.4% over 30 days and down 63.2% from its 52-week high of $3.72, and the company reported a net loss of $5.0M against quarterly revenue of $46.0K with annual revenue growth declining 28.8%, indicating fundamental deterioration. The recurrence of buy activity despite this unfavorable combination of technical weakness, fundamental losses, and the insider's own poor historical timing at this ticker warrants attention to whether capital constraints or other pressures are driving these purchases rather than conviction in recovery.

Director Patel purchases 10,000 COCH shares at $1.46; stock -60.2% from 52-week high, company unprofitable with -28.8% revenue decline

Mona Chetan Patel, a Director, purchased 10,000 shares at $1.46 on 2025-06-06, increasing her holdings by 133.3% to 17,500 shares. The timing warrants caution: at $1.48 current price, the stock is -60.2% from its 52-week high of $3.72, yet her prior three purchases at COCH have all resulted in negative 90-day returns (-27.6%, -36.8%, -19.8%, -35.7%, and -10.9%, -31.2%), with a 0% win rate at this ticker. Fundamentally, Envoy Medical reported a net loss of $-5.0M against quarterly revenue of $46.0K, with annual revenue declining 28.8% year-over-year and a market cap of only $31.6M. The director's accumulation pattern at a distressed valuation does not offset the company's deepening profitability and growth challenges.

Director Patel buys 2,500 shares of COCH at $2.28, holding now 7,500 shares; stock down -78.1% from 52-week high amid unprofitability.

Director Mona Chetan Patel purchased 2,500 shares at $2.28 on 2024-11-20, increasing her holdings by 50.0% from 5,000 to 7,500 shares. The transaction occurs while the stock trades at $2.18, down -78.1% from its 52-week high of $9.95 and has declined -15.2% over 30 days. At the same ticker, Patel's prior two purchases (2024-09-11 and 2024-09-09) recorded negative 30-day returns of -19.8% and -10.9% respectively. The company is unprofitable with net income of $-6.0M despite quarterly revenue of $56.0K and positive annual growth of +33.3%, creating a high-risk profile. The buy pattern—accumulating shares into a depressed stock with a weak near-term trend and unfavorable prior-trade outcomes at this ticker—reflects continued exposure to a speculative position without evidence of improved fundamentals or price stabilization.

Director Patel acquired 5,000 shares (5.0K shares) for $16,520.00 ($16.5K) at blended average price $3.30 in 2 purchases; stock now $3.18, down 68.0% from 52-week high of $9.95.

Patel Mona Chetan, a Director at Envoy Medical (COCH), made an initial equity investment in the company through 2 separate open-market purchases totaling 5,000 shares for $16,520.00 between September 9–11, 2024. At the time of purchase, the blended average price was $3.30 per share; the stock now trades at $3.18, and has declined 68.0% from its 52-week high of $9.95. The company reported $68,000.00 revenue in the latest quarter against net income of $-3.9M, with full-year results also negative, though annual revenue growth reached 33.3%. This acquisition by a Director during a period of significant stock weakness (currently trading near recent lows within its 52-week range) warrants examination of what drove the purchase decision at this valuation—particularly given the company's persistent unprofitability.